Form D · Biotechnology
Epiodyne, Inc.
San Francisco, CA · CIK 0001674182
Offering snapshot reported Apr 24, 2019 · SEC filing
- Reported sold
- $8M Offering amount: $8M
- Investors reported
- 13 Form D · investor count
- Minimum accepted
- $0 Reported outside-investor minimum
- First sale
- Jul 10, 2018 As reported in this filing
What changed?
Latest filing versus its linked predecessor, where available.
No comparable changes in the displayed metrics.
Filing history
Scroll to see all columns →
| Filed | Filing type | Reported sold | Change vs linked filing | Investors | Source |
|---|---|---|---|---|---|
| Apr 24, 2019 | Initial | $7,999,997 | No comparison | 13 | SEC filing |
| Nov 15, 2017 | Initial | $5,780,340 | No comparison | 3 | SEC filing |
| Jun 15, 2016 | Initial | $500,000 | No comparison | 2 | SEC filing |
Offering details
- Securities
- Equity
- Exemptions
- 06b
- Duration over one year
- No
- Business combination
- No
- Sales commissions
- $0
- Finders' fees
- $0
- Form D file number
- 021-337965
Source: Form D, filed Apr 24, 2019. Minimum accepted may differ from a standard advertised minimum.
Fund connections
No confirmed ADV fund connection is available for this issuer.
People & organizations
Current and past Form D appearances. These existing records do not establish a person's current role or uniquely identify them across issuers.
| Name | Reported role |
|---|---|
| Brook Byers | Director |
| Douglas Crawford | Director |
| Brian Shoichet | Director |
| Alex Tkachenko | Director, Executive |
Issuer details
Industry: Biotechnology (See others in industry)
Address:
953 Indiana Street
San Francisco, CA, 94107
San Francisco, CA, 94107